CD80 and rheumatoid arthritis: On the basis of these observations, our results suggest that continuous treatment with CTLA-4-Ig may lead to a blocking or reduction of CD80 and CD86 on the surface of the memory B cells in the blood of the RA patients for at least 1 to 2 months in vivo.